Corporate Members

Diamond Elite





Latest News


RECORDED WEBINAR Learn about the ways in which CAR T-cell therapy treats blood cancer, what CAR T therapy means for the future of cancer treatment, and the current patient access environment and other key considerations. PRESENTERS Frederick Locke, MD, Moffitt Cancer Center Krishna V. Komanduri, MD, Sylvester Comprehensive Cancer Center Brian Koffman, MD, CLL Society,...

FDA Approves Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

On November 6, the U.S. Food and Drug Administration (FDA) approved elotuzumab (Empliciti) injection for intravenous use in combination with pomalidomide (Pomalyst) and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide (Revlimid) and a proteasome inhibitor. In ELOQUENT-3, a randomized, open-label, phase II trial, elotuzumab...

FDA grants accelerated approval to pembrolizumab for hepatocellular carcinoma

On November 9, 2018, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. For additional information, please click here. Approval was based on KEYNOTE 224 (NCT02702414), a single-arm, multicenter trial enrolling 104 patients with hepatocellular carcinoma....

Merck is pleased to announce that KEYTRUDA in combination with carboplatin and either paclitaxel or nab-paclitaxel has been approved by the FDA for the first-line treatment of patients with metastatic squamous NSCLC

KEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the ·    First-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations KEYTRUDA is also indicated as a single agent for the ·    First-line treatment of patients with metastatic NSCLC whose tumors have high PD-L1 expression (TPS ≥50%) as...

Florida Cancer Specialists & Research Institute, LLC Names Dr. Lucio Gordan as New Managing Partner and President

Fort Myers, Florida – October 31, 2018… Florida Cancer Specialists & Research Institute, LLC (FCS) the largest physician-owned oncology/hematology practice in the country, today announced that Dr. Lucio Gordan has been named Managing Partner and President of FCS. Dr. Gordan, a hematologist/oncologist, replaces Dr. William Harwin, who notified the Board of Directors of his decision to step down this weekend. Dr....

Who’s Online

There are no users currently online